CA2065361A1 - Apparatus for genetic transformation - Google Patents

Apparatus for genetic transformation

Info

Publication number
CA2065361A1
CA2065361A1 CA002065361A CA2065361A CA2065361A1 CA 2065361 A1 CA2065361 A1 CA 2065361A1 CA 002065361 A CA002065361 A CA 002065361A CA 2065361 A CA2065361 A CA 2065361A CA 2065361 A1 CA2065361 A1 CA 2065361A1
Authority
CA
Canada
Prior art keywords
unit
hand
hand unit
convenient
genetic transformation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002065361A
Other languages
French (fr)
Other versions
CA2065361C (en
Inventor
Dennis E. Mccabe
Brian J. Martinell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Dennis E. Mccabe
Brian J. Martinell
Agracetus, Inc.
Auragen, Inc.
Powderject Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dennis E. Mccabe, Brian J. Martinell, Agracetus, Inc., Auragen, Inc., Powderject Vaccines, Inc. filed Critical Dennis E. Mccabe
Publication of CA2065361A1 publication Critical patent/CA2065361A1/en
Application granted granted Critical
Publication of CA2065361C publication Critical patent/CA2065361C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C12N15/8207—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers

Abstract

An apparatus for the particle mediated gen-etic transformation of organisms in vivo has two parts, a support unit and a hand unit (34). The hand unit (34) is of a convenient hand manipulable size so that it can be placed readily against the or-ganism the cells of which are to be transformed.
The hand unit (34) is connected to the suport unit by a flexible umbilical (56, 68) so that the hand unit (34) can be placed where desired. The apparatus is particularly well adapted for the convenient trans-formation of somatic cells of whole animals or hu-mans.
CA002065361A 1990-06-21 1991-06-21 Apparatus for genetic transformation Expired - Lifetime CA2065361C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/541,563 US5149655A (en) 1990-06-21 1990-06-21 Apparatus for genetic transformation
PCT/US1991/004389 WO1991019781A1 (en) 1990-06-21 1991-06-21 Apparatus for genetic transformation
US541,563 1995-10-10

Publications (2)

Publication Number Publication Date
CA2065361A1 true CA2065361A1 (en) 1991-12-22
CA2065361C CA2065361C (en) 2002-04-23

Family

ID=24160120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065361A Expired - Lifetime CA2065361C (en) 1990-06-21 1991-06-21 Apparatus for genetic transformation

Country Status (7)

Country Link
US (1) US5149655A (en)
EP (1) EP0487711B1 (en)
AT (1) ATE158020T1 (en)
AU (1) AU639649B2 (en)
CA (1) CA2065361C (en)
DE (1) DE69127606T2 (en)
WO (1) WO1991019781A1 (en)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3573454B2 (en) * 1989-06-26 2004-10-06 パウダージェクト ヴァクシンズ，インコーポレイテッド Particle-mediated transformation of animal somatic cells
AU2146092A (en) * 1992-05-28 1993-12-30 Scientific Dimensions Usa, Inc. Transgenic animal production with biolistically transformed spermatozoa
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5405779A (en) * 1993-04-09 1995-04-11 Agracetus, Inc. Apparatus for genetic transformation
CA2166380A1 (en) * 1993-06-30 1995-01-12 Sandra G. Fitzpatrick-Mcelligott Method for introducing a biological substance into a target
US5506125A (en) * 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
CN1112943C (en) * 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 Gas driven gene delivery instrument
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5780100A (en) * 1995-05-18 1998-07-14 Powderject Vaccines, Inc. Method and apparatus for preparing sample cartridges for particle acceleration device
US5525510A (en) * 1995-06-02 1996-06-11 Agracetus, Inc. Coanda effect gene delivery instrument
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
US6013050A (en) * 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
US5753477A (en) * 1996-03-19 1998-05-19 University Technology Corporation Magneto-biolistic methods
US5922685A (en) * 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
WO1997047730A1 (en) * 1996-06-14 1997-12-18 Powderject Vaccines, Inc. Sample delivery module for particle acceleration apparatus
US6893664B1 (en) 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5733600A (en) * 1996-11-13 1998-03-31 Powderject Vaccines, Inc. Method and apparatus for preparing sample cartridges for a particle acceleration device
EP0957980A4 (en) * 1996-11-27 2000-03-29 Gen Hospital Corp Compound delivery using impulse transients
US6200959B1 (en) 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US5947928A (en) * 1997-06-19 1999-09-07 Mile Creek Capital, Llc Drug delivery system
US5994624A (en) * 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6060315A (en) * 1997-12-01 2000-05-09 Lockheed Martin Energy Research Corporation Method for facilitating the introduction of material into cells
US6284345B1 (en) * 1997-12-08 2001-09-04 Washington University Designer particles of micron and submicron dimension
PT1047784E (en) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Neissera meningitidis antigens
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CA2256121A1 (en) * 1998-06-08 1999-12-08 Hong Wang Cyclin-dependent kinase inhibitors as plant growth regulators
US6365802B2 (en) * 1998-08-14 2002-04-02 Calgene Llc Methods for increasing stearate content in soybean oil
WO2000013573A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Monitoring methods using particle delivery methods
US6602678B2 (en) 1998-09-04 2003-08-05 Powderject Research Limited Non- or minimally invasive monitoring methods
DK1123396T3 (en) * 1998-10-19 2006-07-10 Powderject Vaccines Inc Minimal promoters and uses thereof
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000047227A2 (en) 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US7060048B1 (en) 1999-04-16 2006-06-13 Powerject Research Limited Needleless syringe
PT1228217E (en) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6815579B1 (en) 1999-07-22 2004-11-09 The University Of British Columbia Plant long chain fatty acid biosynthetic enzyme
CA2284246A1 (en) 1999-10-01 2001-04-01 Agriculture And Agrifood Canada Of Agriculture And Agri-Food Plant fatty acid desaturases and alleles therefor
ES2564463T3 (en) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
US20040234539A1 (en) * 1999-11-03 2004-11-25 Powderject Research Limited Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
EP1232264B1 (en) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Human fgf-21 gene and gene expression products
BRPI0107679B8 (en) 2000-01-17 2021-05-25 Chiron Spa composition comprising Neisseria meningitidis serum group b outer membrane vesicles and an inorganic component and use thereof
US8143195B2 (en) * 2000-01-24 2012-03-27 Yingjian Wang Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays
US7429466B2 (en) * 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
AU6162501A (en) 2000-05-16 2001-11-26 Univ Minnesota High mass throughput particle generation using multiple nozzle spraying
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US6706032B2 (en) * 2000-06-08 2004-03-16 Massachusetts Institute Of Technology Localized molecular and ionic transport to and from tissues
ES2305087T3 (en) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. POLINUCLEOTIDOS RELATED TO CANCER DE COLON.
FR2811323B1 (en) * 2000-07-07 2006-10-06 Fuma Tech Gmbh HYBRID MATERIAL, USE OF SAID HYBRID MATERIAL, AND METHOD OF MANUFACTURING THE SAME
EP1366154A2 (en) 2000-09-15 2003-12-03 Her Majesty in right of Canada as represented by The Minister of Agricuture and Agri-Food Canada, Saskatoon Research Center Modulation of meiotic recombination
GB0025147D0 (en) 2000-10-13 2000-11-29 Torsana Diabetes Diagnostics A Optical sensor for in situ measurement of analytes
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
US8716022B2 (en) * 2000-11-17 2014-05-06 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Modulation of meiotic recombination
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
CA2340998C (en) 2001-03-21 2012-01-03 Saskatchewan Wheat Pool Selective modification of plant fatty acids
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
KR20030022094A (en) * 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 Novel keratinocyte growth factor-2 analogue in hair follicle
US8061006B2 (en) * 2001-07-26 2011-11-22 Powderject Research Limited Particle cassette, method and kit therefor
US6612459B2 (en) * 2001-09-04 2003-09-02 Todd Young Nestable multiple compartment tray for faux painting material and applicators
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
WO2003050258A2 (en) * 2001-12-07 2003-06-19 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
DE60326931D1 (en) * 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic DIFFERENTIALLY EXPRESSED GENEVA PRODUCTS AND THEIR USE PROCEDURES IN CANNULAR MAMMA CELLS
EP1501855A4 (en) * 2002-03-21 2006-02-22 Sagres Discovery Inc Novel compositions and methods in cancer
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
EP2302039A1 (en) 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
US20040049800A1 (en) * 2002-06-13 2004-03-11 Kopin Alan S. Rapid methods for assessing therapeutic activity using animals expressing constitutively active G protein coupled receptors
CA2500215C (en) * 2002-09-27 2012-02-28 Powderject Research Limited Nucleic acid coated particles
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
US8147426B2 (en) * 2003-12-31 2012-04-03 Nipro Diagnostics, Inc. Integrated diagnostic test system
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
ATE552267T1 (en) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic IMMUGENES OF UROPATHOGENS ESCHERICHIA COLI
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
AU2006235258A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
EP2529761B1 (en) 2006-01-31 2017-06-14 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
WO2007147167A2 (en) * 2006-06-16 2007-12-21 Porous Power Technologies, Llc Optimized microporous structure of electrochemical cells
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
US9040816B2 (en) * 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
WO2008091546A1 (en) * 2007-01-22 2008-07-31 Seashell Technology Llc. Composite and layered particles for efficient delivery of polyelectrolytes
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0718029D0 (en) * 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20090208832A1 (en) * 2008-02-17 2009-08-20 Porous Power Technologies, Llc Lamination Configurations for Battery Applications Using PVDF Highly Porous Film
US20090227163A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Protective Apparel with Porous Material Layer
US20090222995A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Bedding Applications for Porous Material
US20090223155A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Building Construction Applications for Porous Material
US20090226683A1 (en) * 2008-03-05 2009-09-10 Bernard Perry Porous Material Uses in Furniture
US9839772B2 (en) 2008-05-06 2017-12-12 Cook Medical Technologies Llc Apparatus and methods for delivering therapeutic agents
WO2010074949A1 (en) 2008-12-23 2010-07-01 Wilson-Cook Medical Inc. Apparatus and methods for containing and delivering therapeutic agents
US20100178567A1 (en) * 2008-12-24 2010-07-15 Porous Power Technologies, Llc Mat Forming Spacers in Microporous Membrane Matrix
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
CN102804297A (en) 2009-05-20 2012-11-28 多孔渗透电力技术公司 Treatment and adhesive for microporous membranes
US9101744B2 (en) 2009-05-29 2015-08-11 Cook Medical Technologies Llc Systems and methods for delivering therapeutic agents
US8118777B2 (en) 2009-05-29 2012-02-21 Cook Medical Technologies Llc Systems and methods for delivering therapeutic agents
EP2451833B1 (en) 2009-07-07 2018-01-17 GlaxoSmithKline Biologicals SA Conserved escherichia coli immunogens
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US8692064B2 (en) * 2009-10-02 2014-04-08 The Curators Of The University Of Missouri Quantitative trait loci associated with soybean cyst nematode resistance and methods of their use
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US8730643B2 (en) * 2010-10-22 2014-05-20 Sca Hygiene Products Ab Apparatus with arc generator for dispensing absorbent sheet products
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
US9867931B2 (en) 2013-10-02 2018-01-16 Cook Medical Technologies Llc Therapeutic agents for delivery using a catheter and pressure source
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
AU2017232723B2 (en) 2016-03-15 2023-04-20 National Research Council Of Canada Modulating plant abiotic stress responses using the kanghan gene family
US11859196B2 (en) 2016-03-15 2024-01-02 National Research Council Of Canada Modulating drought tolerance in Brassicaceae using the Kanghan gene family
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
US11377662B2 (en) 2018-01-10 2022-07-05 Wisconsin Alumni Research Foundation Agrobacterium-mediated and particle bombardment transformation method for cowpea and dry bean meristem explants
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574734A5 (en) * 1973-10-12 1976-04-30 Dornier System Gmbh
US4302670A (en) * 1978-06-27 1981-11-24 Claude E. Corson Electrogenic seed treater
WO1985001856A1 (en) * 1983-11-03 1985-05-09 Johannes Martenis Jacob De Wet Method for the transfer of exogenous genes in plants using pollen as a vector
DE3585638D1 (en) * 1984-05-11 1992-04-23 Ciba Geigy Ag TRANSFORMATION OF PLANT HERITAGE.
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4879993A (en) * 1986-10-29 1989-11-14 Siemens Aktiengesellschaft Shock wave source for generating a short initial pressure pulse
US4715376A (en) * 1986-11-07 1987-12-29 Trutek Research, Inc. Isolation of gas in hydraulic spark gap shock wave generator
US5015580A (en) * 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
IL84459A (en) * 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
EP0331855B1 (en) * 1988-02-29 1995-03-08 E.I. DU PONT DE NEMOURS & COMPANY, INC. Apparatus for delivering substances into cells and tissues in a non-lethal manner
JP3573454B2 (en) * 1989-06-26 2004-10-06 パウダージェクト ヴァクシンズ，インコーポレイテッド Particle-mediated transformation of animal somatic cells

Also Published As

Publication number Publication date
EP0487711A1 (en) 1992-06-03
EP0487711A4 (en) 1993-02-17
ATE158020T1 (en) 1997-09-15
EP0487711B1 (en) 1997-09-10
AU8210891A (en) 1992-01-07
AU639649B2 (en) 1993-07-29
CA2065361C (en) 2002-04-23
WO1991019781A1 (en) 1991-12-26
DE69127606T2 (en) 1998-03-05
US5149655A (en) 1992-09-22
DE69127606D1 (en) 1997-10-16

Similar Documents

Publication Publication Date Title
CA2065361A1 (en) Apparatus for genetic transformation
NZ232834A (en) Reproducing coniferous plants by somatic embrogenesis using plant tissue culturing techniques
AU8045391A (en) Amplification of midivariant dna templates
NZ224920A (en) 1,2-diazoles, 3-phenoxy derivatives thereof and their use as herbicides
GB9115680D0 (en) Growing medium
GB9021319D0 (en) Growing medium
GB8917391D0 (en) Implements with handles
GB2244988B (en) Conditioning growing medium or mulching
HU912929D0 (en) Inactivation of gene transcription in plants by means of modified transcription activators
WO1996007389A3 (en) Individual environmental control apparatus
EP0598269A3 (en) Apparatus for the culture of living cells and tissues.
GB9312265D0 (en) Improvements in soil cultivation
AU2570992A (en) Tryptophan analogues as selective agents in the transformation of plants and plant cells
OA09806A (en) Horse driven hitch cart
AU7481391A (en) Engrafting allogeneic tissues or organs using interleukin
CA2142080A1 (en) Electrical connector
EP0721544A4 (en) Propulsion apparatus driven by environment's heat
Thorpe Articulations of the text; rewriting Frances Burney.
CS278590A2 (en) Biological treatment plant
AU562347B3 (en) Power driven golf buggy
CS604287A1 (en) Equipment for soil cultivation in gardens and vineyards
GB9211991D0 (en) Improvements in or relating to the cultivation of conifers
AU590404B2 (en) Improvements in gardening implements
GB8923534D0 (en) Universal plant aider
AU8397491A (en) Aeration apparatus with draft tube

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry